Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Takakazu Sugita"'
Autor:
Hidefumi Inaba, Yosuke Kaido, Saya Ito, Tomonao Hirobata, Gen Inoue, Takakazu Sugita, Yuki Yamamoto, Masatoshi Jinnin, Hiroaki Kimura, Tomoko Kobayashi, Shintaro Iwama, Hiroshi Arima, Takaaki Matsuoka
Publikováno v:
Endocrinology and Metabolism, Vol 37, Iss 1, Pp 84-95 (2022)
Background Type 1 diabetes mellitus induced by immune-checkpoint inhibitors (ICI-T1DM) is a rare critical entity. However, the etiology of ICI-T1DM remains unclear. Methods In order to elucidate risk factors for ICI-T1DM, we evaluated the clinical co
Externí odkaz:
https://doaj.org/article/c45b318caf02452b8156842046da086d
Autor:
Satoshi Terashita, Keiichiro Suminaga, Hiroaki Kawachi, Susumu Noguchi, Tatsuyoshi Ikeue, Takakazu Sugita
Publikováno v:
Respirology Case Reports, Vol 8, Iss 6, Pp n/a-n/a (2020)
Abstract Medical thoracoscopy is a minimally invasive single‐port endoscopic technique that provides direct visualization of the pleural surface and allows for diagnostic procedures. The diagnostic yield of medical thoracoscopy is high and is gener
Externí odkaz:
https://doaj.org/article/fa38b3c15a3b4d3bb4185b40dadefb26
Intrapleural urokinase directly under medical thoracoscopy for the diagnosis of tuberculous pleurisy
Autor:
Satoshi Terashita, Hiroaki Kawachi, Tomoko Tajiri, Susumu Noguchi, Tatsuyoshi Ikeue, Takakazu Sugita
Publikováno v:
Respirology Case Reports, Vol 8, Iss 1, Pp n/a-n/a (2020)
Medical thoracoscopy, also called “local anesthetic thoracoscopy” and “pleuroscopy,” is a minimally invasive single‐port endoscopic technique that provides direct visualization of the pleural surfaces and channels to conduct diagnostic and
Externí odkaz:
https://doaj.org/article/55d6ace05f9a4de8862316d9e0ca8685
Autor:
Susumu Noguchi, Hiroaki Kawachi, Hiroshi Yoshida, Akari Fukao, Satoshi Terashita, Tatsuyoshi Ikeue, Sadao Horikawa, Takakazu Sugita
Publikováno v:
Case Reports in Oncology, Vol 11, Iss 2, Pp 562-566 (2018)
Nivolumab, an anti-PD-1 antibody, inhibits binding between PD-1 and PD-1 ligand and activates antigen-specific T cells that have become unresponsive to cancer cells. Although it is recommended as a second-line therapy in gene mutation-negative non-sm
Externí odkaz:
https://doaj.org/article/e3fee75e597e4012acce1622ffc1eabd
Autor:
Hiroaki Kawachi, Takahiro Kaki, Susumu Noguchi, Takakazu Sugita, Tatsuyoshi Ikeue, Keiichiro Suminaga, Akari Fukao, Sadao Horikawa, Satoshi Terashita
Publikováno v:
Lung Cancer: Targets and Therapy. 11:53-57
Purpose The effects of immune checkpoint inhibitors have been reported to be linked with immune-related adverse events (irAEs). In patients with advanced non-small-cell lung cancer, who tested positive for programmed death-ligand 1 (PD-L1), pembroliz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ec36c2929b90367cda5ba6680d5131c
https://doi.org/10.2147/lctt.s254146
https://doi.org/10.2147/lctt.s254146
Autor:
Akari Fukao, Tomoko Tajiri, Susumu Noguchi, Takakazu Sugita, Sadao Horikawa, Eiichiro Tanaka, Hiroaki Kawachi, Hiroshi Yoshida, Tatsuyoshi Ikeue, Satoshi Terashita
Publikováno v:
Internal Medicine
Lymphoproliferative disorders can occur in patients with autoimmune disorders who undergo long-term methotrexate therapy (MTX-LPD). Although the manifestations of MTX-LPD are diverse, little attention is paid to endobronchial involvement. We herein d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45486849244362df945a503ce838a474
https://doi.org/10.2169/internalmedicine.2109-18
https://doi.org/10.2169/internalmedicine.2109-18
Autor:
Yoshinori Hasegawa, Masaya Akai, Masahiro Oi, Isao Ito, Keisuke Tomii, Hideo Kita, Hiroaki Yasui, Takashi Yamada, Hitomi Ajimizu, Toyohiro Hirai, Naoya Tanabe, Kazuo Endo, Ken-ichi Takahashi, Daiki Inoue, Satoru Terada, Kojiro Otsuka, Kohei Fujita, Yusuke Kaji, Kazutaka Hosoya, Masahito Emura, Hiromi Tomioka, Kensuke Nishioka, Takakazu Sugita, Issei Oi, Hiroshi Shima, Hitokazu Tsukao, Michiko Tsuchiya, Nobuyoshi Hamao, Tadashi Ishida, Akihiro Ito, Yusuke Shiraishi, Hisako Matsumoto, Masahiro Shirata, Toru Kojima, Masatoshi Yamazoe, Hitoshi Nakaji, Tatsuya Ogimoto, Motonari Fukui, Masataka Hirabayashi, Atsushi Nakagawa
Publikováno v:
Open Forum Infectious Diseases
Background Detailed differences in clinical information between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia (CP), which is the main phenotype of SARS-CoV-2 disease, and influenza pneumonia (IP) are still unclear. Methods A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1dced238c58b03dd158e6424adc944c
https://pubmed.ncbi.nlm.nih.gov/34291119
https://pubmed.ncbi.nlm.nih.gov/34291119
Autor:
Hiroaki Kawachi, Susumu Noguchi, Tatsuyoshi Ikeue, Takakazu Sugita, Satoshi Terashita, Keiichiro Suminaga
Publikováno v:
Respirology Case Reports
Respirology Case Reports, Vol 8, Iss 6, Pp n/a-n/a (2020)
Respirology Case Reports, Vol 8, Iss 6, Pp n/a-n/a (2020)
Medical thoracoscopy is a minimally invasive single‐port endoscopic technique that provides direct visualization of the pleural surface and allows for diagnostic procedures. The diagnostic yield of medical thoracoscopy is high and is generally base
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f29e25f8239ef297f2ee92f0dbc0cfd
https://doi.org/10.1002/rcr2.616
https://doi.org/10.1002/rcr2.616
Autor:
Akari Fukao, Takakazu Sugita, Hiroshi Yoshida, Satoshi Terashita, Sadao Horikawa, Tatsuyoshi Ikeue, Susumu Noguchi, Hiroaki Kawachi
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 11, Iss 2, Pp 562-566 (2018)
Case Reports in Oncology, Vol 11, Iss 2, Pp 562-566 (2018)
Nivolumab, an anti-PD-1 antibody, inhibits binding between PD-1 and PD-1 ligand and activates antigen-specific T cells that have become unresponsive to cancer cells. Although it is recommended as a second-line therapy in gene mutation-negative non-sm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cfea456709637a74b472cfd27aa8570
http://europepmc.org/articles/PMC6120371
http://europepmc.org/articles/PMC6120371
Autor:
Mitsunori Morita, Takehiro Yasuda, Satoshi Hara, Naoki Sakai, Keisuke Tomii, Motonari Fukui, Yasushi Fukuda, Toyohiro Hirai, Masataka Hirabayashi, Manabu Ishitoko, Tadashi Ishida, Moon Hee Hwang, Hitoshi Nakaji, Takakazu Sugita, Yuki Kataoka, Hiroshige Yoshioka, Takeshi Morimoto, Tadashi Mio, Daichi Fujimoto, Young Hak Kim
Publikováno v:
Lung Cancer. 119:14-20
Introduction Nivolumab has been shown to be effective and safe in previously treated patients with advanced non-small cell lung cancer (NSCLC). However, little is known regarding its performance in real-world (i.e., non-trial) settings. Furthermore,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::215d5b4a649eab1ea4777853e65d9af8
https://doi.org/10.1016/j.lungcan.2018.02.017
https://doi.org/10.1016/j.lungcan.2018.02.017